The goal of this clinical trial is to learn if Fenugreek seed powder helps lower body weight and blood sugar in adults with type 2 diabetes who are overweight or obese. The main questions it aims to answer are:

Does Fenugreek lower body mass index (BMI)? Does Fenugreek lower fasting blood sugar, random blood sugar, and HbA1c levels? Researchers will compare people who take Fenugreek along with their regular diabetes care to people who receive only standard diabetes care, to see if the Fenugreek supplement adds extra benefits.

Participants will:

Take 10 grams of Fenugreek seed powder twice a day (before breakfast and dinner) for 3 months.

Follow their usual diabetes treatment and a recommended meal plan. Visit the clinic four times during the study to check weight and blood sugar levels.

This study is being done in Hail City, Saudi Arabia.

This clinical trial tested whether Fenugreek seed powder, a natural dietary supplement, could help lower blood sugar and reduce body weight in adults with type 2 diabetes. The study was conducted in Hail City, Saudi Arabia, and involved 80 participants who were either overweight or obese and diagnosed with type 2 diabetes.

Participants were assigned to one of two groups:

The intervention group received 10 grams of Fenugreek seed powder twice daily (before breakfast and dinner) for three months, in addition to their usual diabetes treatment and a standard meal plan.

The control group received only their standard diabetes care and meal plan, without the Fenugreek supplement.

The study used a quasi-experimental pretest-posttest design. Participants' weight (BMI), fasting blood sugar (FBS), random blood sugar (RBS), and HbA1c were measured at the start and monitored throughout the three-month period. Data were collected from local clinics and hospitals that serve people with diabetes in the region.

This study aims to provide evidence on the potential role of Fenugreek as a safe, culturally accepted, and cost-effective supplement that can support diabetes management and reduce obesity-related complications in the Saudi population

Inclusion Criteria:

Adults aged 18 years or older

Diagnosed with type 2 diabetes mellitus

Body Mass Index (BMI) classified as overweight or obese

Receiving standard diabetes treatment (e.g., oral hypoglycemic agents)

Able and willing to provide informed consent

Residing in Hail City, Saudi Arabia

Exclusion Criteria:

Diagnosed with type 1 diabetes mellitus

Currently using insulin therapy

Pregnant or breastfeeding women

Known allergy or sensitivity to Fenugreek

Diagnosed gastrointestinal diseases or malabsorption conditions

Participation in another clinical trial within the past 3 months

Any serious medical or psychiatric condition that, in the opinion of the investigators, could interfere with study participation

-

There is no plan to share individual participant data (IPD) with other researchers.

The data collected will be used solely for the purposes outlined in the approved research protocol and will remain confidential.

Any future data sharing (if considered) would require additional ethical clearance and participant consent.

All participants, care providers, and investigators were aware of the intervention.